Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7650648 | 0.90 | CHRNB2 (0.44) | JAK2JAK1GPR119NAMPT | |
| SCHEMBL6621388 | 0.89 | HSD11B1 (0.42) | JAK2JAK1KMT2AL3MBTL1HSD11B1 | |
| SCHEMBL649847 | 0.87 | KCNK3 (0.55) | JAK2JAK1GPR119STSNAMPT | |
| SCHEMBL584450 | 0.87 | KCNK3 (0.55) | JAK2JAK1GPR119STSNAMPT | |
| SCHEMBL16053284 | 0.87 | KCNK3 (0.55) | JAK2JAK1GPR119STSNAMPT | |
| Hydrochloric Acid SCHEMBL6093599 | 0.86 | KCNK3 (0.54) | JAK2JAK1GPR119STSNAMPT | |
| Hydrochloric Acid SCHEMBL6095348 | 0.86 | KCNK3 (0.54) | JAK2JAK1GPR119STSNAMPT | |
| SCHEMBL18497493 | 0.85 | NAMPT (0.51) | JAK2JAK1GPR119STSNAMPT | |
| SCHEMBL584365 | 0.85 | GPR119 (0.46) | JAK2JAK1GPR119STSNAMPT | |
| SCHEMBL927653 | 0.84 | HSD11B1 (0.55) | JAK2JAK1GPR119KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023138362-A1 | WEE1 INHIBITOR, PREPARATION THEREFOR, AND USE THEREOF | 江苏天士力帝益药业有限公司 | 2023-07-27 | — | — | WO | disclosed |
| US-9580434-B2 | Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes | ATTENUA, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| EP-3052498-A1 | 3,7-DIAZABICYCLO[3.3.1]NONANE CARBOXAMIDES AS ANTITHROMBOTIC AGENTS | Council of Scientific & Industrial Research (IN) | 2016-08-10 | — | — | EP | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160214983-A1 | 3,7-DIAZABICYCLO[3.3.1]NONANE CARBOXAMIDES AS ANTITHROMBOTIC AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-07-28 | — | — | US | disclosed |
| US-6887881-B1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ASTRAZENECA AB (SE) | 2005-05-03 | — | — | US | disclosed |
| EP-1397365-B1 | HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS | NEUROSEARCH AS (DK) | 2005-02-16 | — | — | EP | disclosed |
| US-20050004113-A1 | New bispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2005-01-06 | — | — | US | disclosed |
| US-20040147505-A1 | Novel heteroaryl-diazabicyclo alkanes as cns-modulators | NEUROSEARCH A/S (DK) | 2004-07-29 | — | — | US | disclosed |
| EP-1192154-B1 | BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1192156-B1 | BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2004-02-18 | — | — | EP | disclosed |
| EP-1192155-B1 | NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2003-04-02 | — | — | EP | disclosed |
| US-6465481-B1 | EXHIBIT ELECTROPHYSIOLOGICAL ACTIVITY; MAY BE MORE POTENT AND PRODUCE FEWER SIDE EFFECTS INCLUDING LOWER INCIDENCE OF PROARRHYTHMIAS SUCH AS TORSADES DE POINTES | ASTRAZENECA AB (SE) | 2002-10-15 | — | — | US | disclosed |
| EP-1192154-A1 | BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000076999-A1 | NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147505-A1 | Novel heteroaryl-diazabicyclo alkanes as cns-modulators | CHRNA3, CHRNA5, CHRNA2 | JAK2 2665/4885JAK1 2580/4885GPR119 90/4885 |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | HDAC5, KAT2A, HDAC1 | JAK2 4663/4885JAK1 4662/4885GPR119 1526/4885 |
| US-20160214983-A1 | 3,7-DIAZABICYCLO[3.3.1]NONANE CARBOXAMIDES AS ANTITHROMBOTIC AGENTS | TBXA2R, PDGFRA, TBXAS1 | JAK2 148/4885JAK1 921/4885GPR119 114/4885 |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | JAK2 2307/4885JAK1 3723/4885GPR119 2328/4885 |
| US-20050004113-A1 | New bispidine compounds useful in the treatment of cardiac arrhythmias | DRD2, ADRA1D, KCND2 | JAK2 3221/4885JAK1 3512/4885GPR119 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.